Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SpectraCure P18 System and Verteporfin for Recurrent Prostate Cancer
NCT03067051Phase 2Recruiting
- Sponsor
- SpectraCure
- Start
- Mar 2017
- Primary completion
- Jul 2027
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of verteporfin in prostate cancer (PCa), sponsored by SpectraCure. Primary endpoints: Treatment related adverse events at 4 weeks and Percentage of subjects with negative biopsies at 6 months. Started Mar 2017; status: recruiting.
02
Drugs
verteporfin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03067051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03067051.